Acadian Asset Management
ATRA icon

Acadian Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Acadian Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Sell
38,845
-92,065
-70% -$734K ﹤0.01% 1482
2026
Q1 		$617K Buy
130,910
+76,862
+142% +$469K ﹤0.01% 1305
2025
Q4 		$976K Sell
54,048
-2,368
-4% -$35.3K ﹤0.01% 1120
2025
Q3 		$807K Sell
56,416
-8,739
-13% -$101K ﹤0.01% 1098
2025
Q2 		$502K Sell
65,155
-49,956
-43% -$365K ﹤0.01% 1135
2025
Q1 		$682K Sell
115,111
-9,362
-8% -$81.7K ﹤0.01% 1010
2024
Q4 		$1.66M Sell
124,473
-4,671
-4% -$49.2K ﹤0.01% 814
2024
Q3 		$1.05M Buy
129,144
+9,774
+8% +$83.7K ﹤0.01% 900
2024
Q2 		$1.01M Buy
119,370
+13,823
+13% +$208K ﹤0.01% 981
2024
Q1 		$1.83M Buy
105,547
+34,925
+49% +$620K 0.01% 681
2023
Q4 		$904K Buy
70,622
+49,246
+230% +$1.15M ﹤0.01% 890
2023
Q3 		$789K Sell
21,376
-6,812
-24% -$303K ﹤0.01% 908
2023
Q2 		$1.13M Buy
+28,188
New +$1.59M ﹤0.01% 849
2023
Q1 		– Sell
-18,492
Closed -$1.51M – 1738
2022
Q4 		$1.51M Sell
18,492
-19,724
-52% -$2.06M 0.01% 747
2022
Q3 		$3.61M Buy
+38,216
New +$4.29M 0.02% 489
2020
Q3 		– Sell
-2,323
Closed -$846K – 2165
2020
Q2 		$846K Buy
+2,323
New +$587K ﹤0.01% 1022
2017
Q2 		– Sell
-143
Closed -$73K – 1438
2017
Q1 		$73K Buy
+143
New +$59.2K ﹤0.01% 1174

Other funds holding ATRA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Acadian Asset Management's ATRA Position: Q2 2026 in Review

Acadian Asset Management reduced its Atara Biotherapeutics (ATRA) stake by 70% in Q2 2026, selling an estimated $734K and leaving 38,845 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #1482.

Acadian Asset Management first reported a position in ATRA in Q1 2017 and has held it in 17 quarters since. The position peaked at $3.61M in Q3 2022. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Acadian Asset Management held 38,845 shares of Atara Biotherapeutics worth $444K as of Q2 2026.
  • Acadian Asset Management sold 92,065 Atara Biotherapeutics shares in Q2 2026, an estimated $734K.
  • Atara Biotherapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1482 holding.
  • Acadian Asset Management first reported a position in Atara Biotherapeutics in Q1 2017 and has held it in 17 quarters since.
  • Acadian Asset Management's Atara Biotherapeutics position peaked at $3.61M in Q3 2022.
  • 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.